Gilotrif (Afatinib) 30mg/40mg Tablets | China-Sourced EGFR Inhibitor | GLT

Generic Information: Gilotrif (Afatinib) — China Version

Gilotrif is the brand name of afatinib, a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by Boehringer Ingelheim. The China version covered on this page is supplied in compact 7-tablet strips, available in both 30 mg and 40 mg strengths, and is sourced directly from the manufacturer's Chinese subsidiary, Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd. Gilotrif has been approved in China for the treatment of EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), where it remains a foundational targeted therapy recommended by national and international guidelines.

What Is Gilotrif (Afatinib) Used For?

Gilotrif (afatinib) is used to treat adults with locally advanced or metastatic non-small cell lung cancer whose tumors carry activating EGFR mutations — most commonly exon 19 deletions or the exon 21 L858R substitution. It is also approved for patients with metastatic squamous NSCLC that has progressed on or after platinum-based chemotherapy. Because afatinib covalently and irreversibly binds the ErbB receptor family, it offers durable disease control for patients who test positive for these mutations, making it a cornerstone of EGFR-driven lung cancer care in China.

How Does Gilotrif (Afatinib) Work?

Unlike first-generation EGFR inhibitors that bind reversibly, afatinib forms a permanent covalent bond with the kinase domain of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This irreversible, pan-ErbB blockade shuts down the downstream signaling pathways that drive tumor cell growth and survival. Its broad activity is particularly valuable against uncommon EGFR mutations such as G719X, L861Q, and S768I, giving Gilotrif a differentiated clinical profile among EGFR-targeted therapies.

Indications

Gilotrif is indicated for: (1) first-line treatment of metastatic non-small cell lung cancer with non-resistant EGFR mutations, and (2) treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy. Patient selection requires confirmation of EGFR mutation status through an approved molecular test before initiating therapy.

Dosage

The recommended dose is 40 mg once daily, taken at least one hour before or two hours after a meal. For patients with severe renal impairment, the starting dose is reduced to 30 mg once daily. The 7-tablet strips available here correspond to one week of therapy, and dose adjustments should always be managed by the treating oncologist.

Side Effects

The most common adverse reactions (affecting 20% or more of patients) include diarrhea, acneiform rash, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting, and pruritus. More serious but rare events include interstitial lung disease, severe hepatic toxicity, keratitis, and bullous skin reactions. Patients should be monitored regularly and report persistent diarrhea or new respiratory symptoms promptly.

Storage

Store Gilotrif tablets in the original packaging at room temperature, away from moisture and heat. Keep the strips sealed until use and out of reach of children. Do not crush or split the tablets, and take them whole with water.

Why Choose the China Version of Gilotrif?

The China version of Gilotrif delivers the identical Boehringer Ingelheim molecule at a cost that is meaningfully lower than Western list prices. In China, afatinib is included in the national medical insurance drug list, and the 7-tablet packaging aligns with routine weekly prescribing. Compared with the United States, where a monthly Gilotrif supply can cost well into the thousands of dollars, the China-sourced version is priced substantially lower — by a large margin overall — while originating from the same manufacturer and the same GMP-quality supply chain. This makes the China version a practical, trustworthy option for patients and institutions seeking authentic originator afatinib at a more accessible price.

How to Order Gilotrif (Afatinib) from China

To order China-sourced Gilotrif, contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. We are a Hong Kong-licensed pharmaceutical supplier and can provide documentation, cold-chain guidance where relevant, and shipping support to your destination. Please share the required strength, quantity, and your country so we can confirm availability and delivery terms.

FAQ

Is Gilotrif (afatinib) available in China? Yes. Gilotrif is approved in China and widely available through hospitals and licensed suppliers, in both 30 mg and 40 mg strengths.

What is the difference between Gilotrif and first-generation EGFR inhibitors? Gilotrif is an irreversible, pan-ErbB inhibitor that covalently binds EGFR, HER2 and ErbB4, whereas earlier drugs like gefitinib bind reversibly to EGFR alone. This gives Gilotrif broader and more durable activity, including against uncommon EGFR mutations.

How many tablets come in a strip? The China version is supplied in 7-tablet strips, which is one week of once-daily dosing.

Do I need an EGFR test before taking Gilotrif? Yes. Treatment should only begin after a confirmed EGFR mutation is detected by an approved diagnostic test.